Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECOVER-AUTONOMIC (IVIG)
NCT06305793Phase 2Completed
- Sponsor
- Kanecia Obie Zimmerman
- Start
- May 2024
- Primary completion
- Mar 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of intravenous immunoglobulin G in post-COVID-19 condition (PCC), sponsored by Kanecia Obie Zimmerman. Started May 2024; status: completed.
02
Drugs
intravenous immunoglobulin G
03
Conditions
post-COVID-19 condition (PCC)
Beyond the preview
Go deeper on NCT06305793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06305793.